Pulmonary Arterial Hypertension and Hospitalizations

High-Risk Patients Have Worse Outcomes

REVEAL Registry Hospitalizations and Outcomes

Risk Factors for PAH-Related Hospitalization

PAH-Related Events Associated With Clinical Outcomes and Mortality Landmark Analysis

Definition of Morbidity Events in SERAPHIN and GRIPHON

Association Between Morbidity and Mortality at Any Landmark Time Point*

GRIPHON Predictive Value of Hospitalization and Disease Progression

SERAPHIN Post-Hoc Analyses Time to First PAH-Related Hospitalization

Emotional and Overall Quality of Life Considerations

AMBITION Trial: Confirmed Benefit of Upfront Combination Therapy

ESC/ERS Risk Assessment for Initial Treatment Approach in PAH

Continual Re-Assessment Structured Follow-Up

Individual and Multiparameter Risk Assessment Is Needed

Achieving Low-Risk Status in PAH

French Registry: Low-Risk Criteria Determines Long-Term Prognosis

French Registry: BNP Subset Analysis

Importance of Risk Assessment in French Registry

REVEAL Risk Score 2.0

REVEAL Risk Score 2.0 What Has Changed?

Goal: Get Your Patient to a Low-Risk Status

Palliative Care in PAH: Component of Whole Team Approach

General Measures

Multidisciplinary Approach to Care

Coordination of Local and PH Center of Care Collaborative Approach

Use of Technology and Virtual Visits to Co-Manage Patients

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)